NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--John Rothman, Advaxis’ (OTCBB: ADXS.OB) Vice President of Clinical Development, will be a speaker at this year’s World Vaccine Congress 2007, to be held on October 9th at 4:55 CET (10:55PM ET) at the Palais des Congrès de Lyon in Lyon, France. Dr. Rothman will be disclosing key findings that resulted from the recent Phase I/II trial of Advaxis’ lead vaccine, Lovaxin C, a modified Listeria-based live vaccine for the treatment of cervical cancer. Furthermore, Dr. Rothman will also discuss, “Bacterial Vectors Presenting an Immunological Advantage Over Virus-Based Vaccines.”
